Topics

F. Hoffmann-La Roche Ltd: FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

01:05 EST 4 Dec 2019 | FinanzNachrichten

·Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Basel, 4 Dec...

Original Article: F. Hoffmann-La Roche Ltd: FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

NEXT ARTICLE

More From BioPortfolio on "F. Hoffmann-La Roche Ltd: FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...